Zinzino Sales Surge Driven by North American and South American Growth
Event summary
- Zinzino group revenue increased by 20% year-over-year to SEK 281.2 million in January 2026.
- Sales in Zinzino's core markets rose by 20%, reaching SEK 274.1 million.
- Faun Pharma's external sales grew by 51% to SEK 7.1 million.
- North American sales experienced a dramatic 94% increase, reaching SEK 41.3 million.
- South American sales saw a massive 344% increase, reaching SEK 4.0 million.
The big picture
Zinzino's preliminary January 2026 sales report demonstrates a significant acceleration in growth, particularly in North and South America. This expansion, coupled with the performance of Faun Pharma, suggests a successful geographic diversification strategy. However, the contrasting performance in East Europe highlights potential vulnerabilities within the company's regional market penetration, requiring careful monitoring and strategic adjustments to maintain overall growth momentum.
What we're watching
- Regional Sustainability
- The significant growth in South America, while impressive, warrants scrutiny to determine if this is a sustainable trend or a temporary spike, and whether it is indicative of broader market penetration or a localized phenomenon.
- East Europe Performance
- The 14% decline in East European sales is a concerning outlier against the broader positive trend and requires investigation to understand the underlying causes and potential corrective actions.
- North American Scaling
- Zinzino must carefully manage its rapid expansion in North America to avoid operational bottlenecks and ensure the quality of its distribution network can support the increased volume.
Related topics